These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 27099284

  • 1. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N, Takahara M, Soga Y, Nakano M, Yamauchi Y, Zen K, Kawasaki D, Yokoi H, Tosaka A, Tanaka N, Iida O.
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [Abstract] [Full Text] [Related]

  • 2. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y, Soga Y, Iida O, Shiraki T, Kobayashi Y, Hiramori S, Ando K.
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [Abstract] [Full Text] [Related]

  • 3. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S, Liistro F, Angioli P, Ducci K, Falsini G, Porto I, Ricci L, Ventoruzzo G, Turini F, Bellandi G, Bolognese L.
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1386-92. PubMed ID: 27388828
    [Abstract] [Full Text] [Related]

  • 5. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O, Takahara M, Soga Y, Hirano K, Yamauchi Y, Zen K, Kawasaki D, Nanto S, Yokoi H, Uematsu M, ZEPHYR Investigators.
    JACC Cardiovasc Interv; 2016 Apr 25; 9(8):828-834. PubMed ID: 27101908
    [Abstract] [Full Text] [Related]

  • 6. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S, Hirano K, Nakano M, Muramatsu T, Tsukahara R, Ito Y, Ishimori H.
    J Endovasc Ther; 2015 Jun 25; 22(3):341-9. PubMed ID: 25862363
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K, Fujii K, Kawasaki D, Shibuya M, Fukunaga M, Imanaka T, Tamaru H, Sumiyoshi A, Nishimura M, Horimatsu T, Saita T, Okada K, Kimura T, Honda Y, Fitzgerald PJ, Masuyama T, Ishihara M.
    J Endovasc Ther; 2016 Jun 25; 23(3):424-32. PubMed ID: 27044270
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K, Takahara M, Iida O, Soga Y, Kawasaki D, Nanto S, Yokoi H, Matoba S, ZEPHYR Investigators.
    J Vasc Surg; 2017 Mar 25; 65(3):720-725. PubMed ID: 28073668
    [Abstract] [Full Text] [Related]

  • 13. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
    Antoniou GA, Georgakarakos EI, Antoniou SA, Georgiadis GS.
    Interact Cardiovasc Thorac Surg; 2014 Aug 25; 19(2):282-5. PubMed ID: 24729201
    [Abstract] [Full Text] [Related]

  • 14. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.
    J Endovasc Ther; 2014 Jun 25; 21(3):359-68. PubMed ID: 24915582
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
    Kamioka N, Soga Y, Kuramitsu S, Iida O, Hirano K, Suzuki K, Kawasaki D, Yamaoka T, Suematsu N, Shintani Y, Miyashita Y, Takahashi H, Tsuchiya T, Shinozaki N, Okazaki S, Ando K.
    Catheter Cardiovasc Interv; 2017 Nov 01; 90(5):790-797. PubMed ID: 28722294
    [Abstract] [Full Text] [Related]

  • 18. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
    Schmidt A, Piorkowski M, Görner H, Steiner S, Bausback Y, Scheinert S, Banning-Eichenseer U, Staab H, Branzan D, Varcoe RL, Scheinert D.
    JACC Cardiovasc Interv; 2016 Apr 11; 9(7):715-24. PubMed ID: 27056311
    [Abstract] [Full Text] [Related]

  • 19. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis.
    Ho KJ, Devlin PM, Madenci AL, Semel ME, Gravereaux EC, Nguyen LL, Belkin M, Menard MT.
    J Vasc Surg; 2017 Mar 11; 65(3):734-743. PubMed ID: 27986482
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.